Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
National Center for Research Resources (NCRR) Yale University |
---|---|
Information provided by: | Office of Rare Diseases (ORD) |
ClinicalTrials.gov Identifier: | NCT00004327 |
OBJECTIVES:
I. Evaluate the efficacy of octreotide, a somatostatin octapeptide analog, in decreasing gastrointestinal bleeding in patients with hormone-refractory hereditary hemorrhagic telangiectasia or senile ectasia.
Condition | Intervention | Phase |
---|---|---|
Hereditary Hemorrhagic Telangiectasia Ectasia |
Drug: octreotide |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment |
Estimated Enrollment: | 8 |
Study Start Date: | January 1995 |
PROTOCOL OUTLINE: Patients are treated with subcutaneous injections of octreotide twice a day. The dose is adjusted based on response.
If there is no requirement for transfusions or intravenous iron for 4 weeks and the hemoglobin is greater than 10 mg/dL, therapy is continued for 1 year. If there is no decrease in bleeding after 10 weeks, the patient is removed from study.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics-- Hereditary hemorrhagic telangiectasia or senile ectasia Refractory to or unable to tolerate hormonal therapy, i.e.: Estrogen Progesterone Danazol Gastrointestinal (GI) hemorrhage requiring transfusion within past 3 months Recurrent GI bleeding over more than 1 year At least 4 units packed RBCs transfused within past year OR intravenous iron required more than 4 times within past year No other likely source of hemorrhage determined within past year --Prior/Concurrent Therapy-- Disease hormone-refractory --Patient Characteristics-- No octreotide sensitivity
Study ID Numbers: | 199/11875, YALESM-7893 |
Study First Received: | October 18, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00004327 History of Changes |
Health Authority: | United States: Federal Government |
genetic diseases and dysmorphic syndromes hematologic disorders hereditary hemorrhagic telangiectasia rare disease senile ectasia |
Pathological Conditions, Anatomical Antineoplastic Agents, Hormonal Cardiovascular Abnormalities Dilatation, Pathologic Telangiectasia, Hereditary Hemorrhagic Hematologic Diseases Gastrointestinal Diseases Blood Coagulation Disorders Gastrointestinal Hemorrhage Rare Diseases Vascular Diseases |
Octreotide Hemorrhage Hemostatic Disorders Hormones Somatostatin Hemorrhagic Disorders Digestive System Diseases Vascular Malformations Telangiectasis Hereditary Hemorrhagic Telangiectasia Congenital Abnormalities |
Pathological Conditions, Anatomical Antineoplastic Agents, Hormonal Cardiovascular Abnormalities Dilatation, Pathologic Antineoplastic Agents Hematologic Diseases Telangiectasia, Hereditary Hemorrhagic Gastrointestinal Diseases Gastrointestinal Agents Gastrointestinal Hemorrhage Vascular Diseases Octreotide |
Hemorrhage Hemostatic Disorders Pharmacologic Actions Digestive System Diseases Pathologic Processes Hemorrhagic Disorders Therapeutic Uses Vascular Malformations Telangiectasis Cardiovascular Diseases Congenital Abnormalities |